(19)
(11) EP 3 373 916 A1

(12)

(43) Date of publication:
19.09.2018 Bulletin 2018/38

(21) Application number: 16798345.1

(22) Date of filing: 09.11.2016
(51) International Patent Classification (IPC): 
A61K 9/46(2006.01)
A61K 9/20(2006.01)
A61K 9/00(2006.01)
 A61K 47/02(2006.01)
A61K 31/4035(2006.01)
A61K 9/24(2006.01)
(86) International application number:
PCT/US2016/061076
(87) International publication number:
WO 2017/083348 (18.05.2017 Gazette 2017/20)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 11.11.2015 US 201514938714

(71) Applicant: Celgene Corporation
Summit, NJ 07901 (US)

(72) Inventors:
  • CHEN, Ming
    West Windsor, NJ 08550 (US)
  • HUI, Ho-Wah
    Basking Ridge, NJ 07920 (US)
  • SHEN, Xiaole
    Livingston, NJ 07039 (US)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München
80538 München (DE)

   


(54) CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF